Test Your mCRPC Treatment Decision Knowledge
Reviewed by: HU Medical Review Board | Last reviewed: June 2026 | Last updated: June 2026
Treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) have grown more nuanced as biomarker testing, imaging, and the post-novel-hormonal-therapy (NHT) and post-docetaxel landscapes have evolved. This 5-question clinical challenge sharpens the decision logic that healthcare providers operate in – progression interpretation, germline testing, bone health on long-term androgen deprivation therapy (ADT), geriatric oncology assessment, and taxane-class tolerability.
Clinical Challenge
A 68-year-old patient with mCRPC has been on first-line abiraterone for nine months. Prostate-specific antigen (PSA) has risen for two consecutive measurements; restaging imaging is stable; the patient is asymptomatic. Which next step is most appropriate?
Clinical Challenge
Per current NCCN guidance, all patients with metastatic prostate cancer should be offered germline genetic testing. Which gene-mutation panel is most clinically actionable in mCRPC treatment decisions?
Clinical Challenge
In men with prostate cancer starting long-term ADT, the reported first-year lumbar-spine bone mineral density (BMD) loss is approximately:
Clinical Challenge
A 77-year-old man with mCRPC and an Eastern Cooperative Oncology Group (ECOG) performance status of 1 is being considered for first-line taxane chemotherapy. Which assessment is most appropriate to predict tolerability and inform supportive-care planning?
Clinical Challenge
A common clinical perception is that cabazitaxel produces peripheral neuropathy at rates comparable to docetaxel. What does the available comparative evidence on cabazitaxel safety show?